Precision BioSciences
Clinical Trial Services (CRO) · Health Care
$88.1Mlatest round · Venture round · May 2018 · 8 yr ago
2backers · RA Capital Management, venBio Partners
113team · US Form 5500 (plan participants) · Dec 2024
26stories in the press
Overview
ARCUS Genome Editing. At Precision BioSciences, we are using our novel ARCUS genome-editing technology to develop a new class of medicines designed to overcome and potentially cure hard-to-treat conditions, including rare genetic diseases.
Funding and backers
Total raised
$88.1M
2 rounds on record
Latest round
$88.1M
Venture round · May 2018 · 8 yr ago
Team
113
US Form 5500 (plan participants) · Dec 2024
Backers
2
RA Capital Management, venBio Partners
The money's age
Long since its last round
101 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 1, 2019
Took on debt financing $39.6M · SEC Form D
May 25, 2018
Raised a round Venture round $88.1M · SEC Form D
Apr 2006
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Mar 2019 | $39.6M | — | SEC Form D |
| Venture round | May 2018 | $88.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | PRECISION BIOSCIENCES INC | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Derek JantzExecutive Officer, DirectorSEC Form D
Matthew KaneExecutive Officer, DirectorSEC Form D
Abid AnsariExecutive OfficerSEC Form D
Jeff SmithExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Lindus Health
backs Lindus Health
Similar startupsby what they do, their industry and backers
Explore NAPIGEN for innovative mitochondrial and chloroplast genome editing solutions. Partner with Napp Labs for cutting-edge research!
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome…
Allucent is a contract research organization that runs clinical trials for small and mid-sized biotechnology and pharmaceutical companies…
Lindus Health is an artificial intelligence native contract research organisation that runs clinical trials end to end. Founded in 2021 in…
ProofPilot is a clinical trial platform that gives sponsors direct control over planning, activation, enrollment, and engagement — from…
Visa sponsorship
1
H-1B filings in 12 months
1
Green card filings
$243k
Median offered salary
Who they sponsor
Natural sciences managers
1
In the register as Precision BioSciences, Inc., Durham, NC (+1 more)
Other sponsors in the same field
Crown Bioscience 
Curavit
Daiichi Sankyo 
Curia
Alert me
US Department of Labor · latest filing Nov 24, 2025 · Visa details by country
People
Derek Jantz
Executive Officer, Director
Matthew Kane
Executive Officer, Director
Abid Ansari
Executive Officer
Jeff Smith
Executive Officer
Tony Yao
Director
Robert Adelman
Director
Shalini Sharp
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
venBio PartnersVia a fund
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
DURHAM, N.C., October 08, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that i
Read more
Report
Precision BioSciences stock fell 1.74 percent on October 6
Precision BioSciences stock carried a USD 172.5 million market value on October 7, 2026. Q2 cash of USD 112 million supported a runway through 2028.
Read more
Report
Precision BioSciences (DTIL) Receives a Rating Update from a Top Analyst
Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.
Read more
Report
Precision Biosciences stock holds its Nasdaq listing
Precision Biosciences stock remains listed on Nasdaq as of September 22, 2026. The company develops gene editing products for clinical and research use.
Read more
Report
Precision BioSciences stock trades quietly amid lack of fresh catalysts
Precision BioSciences stock shows no major move as of mid September 2026, with recent fundamentals still defining the picture. The shares remain a small cap biotech play focused on gene editing and immuno-oncology.
Read more
Report
Precision BioSciences Begins First DMD Gene-Editing Trial
Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.
Read more
Report
Report
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 - - Advanced PBGENE-DMD to
Read more
Report
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 30, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1